Migraine in women during climacteric: hormonal influence and treatment strategies
DOI:
https://doi.org/10.60108/ce.306Keywords:
Migraine, climacteric, menopauseAbstract
Migraine is a neurovascular disease whose symptoms can be exacerbated by hormonal fluctuations, such as estrogen deficiency that occurs during menstruation or perimenopause. A literature review was conducted in the PubMed database of articles published in English over the last 5 years with the aim of investigating the influence of hormonal changes on migraine in women during climacteric. The reviewed articles highlight that women with migraines have more sleep disorders, anxiety, depression, hypertension, and vasomotor symptoms during the menopausal transition. Regarding hormonal treatments, non-oral treatments with progesterone, such as the levonorgestrel IUD, are preferred since migraine is often associated with vomiting and the risk posed by using estrogen in women with cardiovascular risk factors. Finally, due to their safety, non-pharmacological treatments should not be underestimated, such as avoiding the use of coffee, tobacco, and alcohol, increasing the intake of magnesium and vitamin E-rich foods, or using herbal remedies like vitex agnus-castus.
References
1. Khandelwal S, Meeta M, Tanvir T. Menopause hormone therapy, migraines, and thromboembolism. Best Pract Res Clin Obstet Gynaecol [Internet]. 2022 [citado el 17 de mayo de 2024]; 81: 31–44. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34974967/
2. Luo J. Association between migraine and anxiety symptoms: Results from the study of women’s health across the nation. J Affect Disord [Internet]. 2021 [citado el 17 de mayo de 2024]; 295: 1229–33. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34706437/
3. MacGregor EA. Menstrual and perimenopausal migraine: A narrative review. Maturitas [Internet]. 2020 [citado el 17 de mayo de 2024]; 142: 24–30. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33158484/
4. Pavlović JM. The impact of midlife on migraine in women: summary of current views. Womens Midlife Health [Internet]. 2020 [citado el 17 de mayo de 2024]; 6 (1). Disponible en: https://pubmed.ncbi.nlm.nih.gov/33042563/
5. Ahmad SR, Rosendale N. Sex and gender considerations in episodic migraine. Curr Pain Headache Rep [Internet]. 2022 [citado el 17 de mayo de 2024] ;26 (7): 505–16. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35679008/
6. Van Lohuizen R, Paungarttner J, Lampl C, MaassenVanDenBrink A, Al-Hassany L. Considerations for hormonal therapy in migraine patients: a critical review of current practice. Expert Rev Neurother [Internet]. 2024 [citado el 17 de mayo de 2024]; 24(1): 55–75. Disponible en: https://pubmed.ncbi.nlm.nih.gov/38112066/
7. Godley F III, Meitzen J, Nahman-Averbuch H, O’Neal MA, Yeomans D, Santoro N, et al. How sex hormones affect migraine: An interdisciplinary preclinical research panel review. J Pers Med [Internet]. 2024 [citado el 17 de mayo de 2024]; 14 (2): 184. Disponible en: https://pubmed.ncbi.nlm.nih.gov/38392617/
8. Krause DN, Warfvinge K, Haanes KA, Edvinsson L. Hormonal influences in migraine — interactions of oestrogen, oxytocin and CGRP. Nat Rev Neurol [Internet]. 2021 [citado el 17 de mayo de 2024]; 17 (10): 621–33. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34545218/
9. Veerabathiran R, Kalarani I, Mohammed V. Genetics of menstrual migraine and their association with female hormonal factors. Ann Indian Acad Neurol [Internet]. 2022 [citado el 17 de mayo de 2024]; 25 (3): 383. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35936591/
10. MacDonald CJ, El Fatouhi D, Madika A-L, Fagherazzi G, Kurth T, Severi G, et al. Association of migraine with incident hypertension after menopause: A longitudinal cohort study. Neurology [Internet]. 2021 [citado el 19 de mayo de 2024]; 97 (1). Disponible en: https://pubmed.ncbi.nlm.nih.gov/33883242/
11. Bugge NS, Grøtta Vetvik K, Alstadhaug KB, Braaten T. Cumulative exposure to estrogen may increase the risk of migraine in women. Cephalalgia [Internet]. 2024 [citado el 17 de mayo de 2024]; 44 (1). Disponible en: https://pubmed.ncbi.nlm.nih.gov/38215242/
12. Ornello R, Caponnetto V, Frattale I, Sacco S. Patterns of migraine in postmenopausal women: A systematic review. Neuropsychiatr Dis Treat [Internet]. 2021 [citado el 19 de mayo de 2024]; 17: 859–71. Disponible en: http://dx.doi.org/10.2147/ndt.s285863
13. Faubion SS, Ghaith S, Kling JM, Mara K, Enders F, Starling AJ, et al. Migraine and sleep quality: does the association change in midlife women? Menopause [Internet]. 2023 [citado el 19 de mayo de 2024]; 30 (4): 376–82. Disponible en: https://pubmed.ncbi.nlm.nih.gov/36720087/
14. Kim S, Lee SB, Hong YJ, Kim Y, Han K, Park JW. The influence of endogenous and exogenous hormonal factors on migraine in spontaneous postmenopausal women: A nationwide population-based study in South Korea. Cephalalgia [Internet]. 2022 [citado el 19 de mayo de 2024] ;42 (4–5): 376–84. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34579561/
15. Ornello R, De Matteis E, Di Felice C, Caponnetto V, Pistoia F, Sacco S. Acute and preventive management of migraine during menstruation and menopause. J Clin Med [Internet]. 2021 [citado el 19 de mayo de 2024]; 10 (11): 2263. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34073696/
16. De Vries Lentsch S, Rubio-Beltrán E, Maassen Van Den Brink A. Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman’s life: Implications for the efficacy and safety of novel antimigraine medications. Maturitas [Internet]. 2021 [citado el 19 de mayo de 2024]; 145: 73–7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33541566/
17. Rustichelli C, Bellei E, Bergamini S, Monari E, Baraldi C, Castro FL, et al. Serum levels of allopregnanolone, progesterone and testosterone in menstrually-related and postmenopausal migraine: A cross-sectional study. Cephalalgia [Internet]. 2020 [citado el 21 de mayo de 2024]; 40 (12): 1355–62. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32588652/
18. Tang B, Yu X, Jiang W, Zhang C, Zhan T, He Y. Clinical significance of serum sex hormones in postmenopausal women with vestibular migraine: potential role of estradiol. J Int Med Res [Internet]. 2021 [citado el 22 de mayo de 2024]; 49 (5): 030006052110163. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34024170/
19. Maleki N, Cheng Y-C, Tu Y, Locascio JJ. Longitudinal course of vasomotor symptoms in perimenopausal migraineurs. Ann Neurol [Internet]. 2019 [citado el 22 de mayo de 2024]; 85 (6): 865–74. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30937949/
20. Dima L, Bălan A, Moga MA, Dinu CG, Dimienescu OG, Varga I, et al. Botulinum toxin a valuable prophylactic agent for migraines and a possible future option for the prevention of hormonal variations-triggered migraines. Toxins (Basel) [Internet]. 2019 [citado el 23 de mayo de 2024]; 11 (8) :465. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31398813/
Additional Files
Published
Issue
Section
License
En caso de que el artículo sea publicado, los autores aceptan transferir todos los derechos del trabajo presentado, incluidos los derechos de autor y aquellos relativos a la transmisión electrónica, exclusivamente a CODEM, de manera universal, en todos los idiomas, una vez que el trabajo haya sido aceptado para su publicación dentro de la revista electrónica CONOCIMIENTO ENFERMERO.
El autor podrá hacer copias ilimitadas del trabajo para uso docente, reutilizarlo en su totalidad o parcialmente en un libro escrito por el autor o hacer copias para su distribución en la institución en la que trabaja. CODEM hará mención al nombre del autor en las publicaciones que se realicen del trabajo.
